Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported a strong start to FY26, with Q1 revenue rising 23.1% YoY to ₹756 Mn, driven by growth across key brands. Operating EBITDA grew 24.1% to ₹157 Mn with margins expanding 17 bps to 20.8%, while net profit more than doubled to ₹108 Mn with PAT margin at 14.3% (up 562 bps YoY). The company strengthened its position to #7 in the Gynae CVM rankings and remains zero-debt with a healthy cash balance of ₹1,609 Mn after adding ₹153 Mn of free cash this quarter. Management provided forward guidance: 15%+ revenue growth and 20%+ Operating EBITDA improvement targeted for FY26, with 12-14% revenue growth and 100-150 bps margin expansion beyond FY26.
Strong quarterly performance with broad-based growth, expanding margins, and a debt-free, cash-rich balance sheet signals healthy operational execution, likely to be viewed positively by investors. The explicit multi-year guidance on revenue and margin expansion, combined with stated intent to use cash for strategic acquisitions, may support sentiment on the stock.